uk.reuters.com — LONDON (Reuters) - Lymphoma patients who continue regular infusions of Genentech Inc and Biogen Idec's Rituxan after chemotherapy may live longer than patients who stop, Israeli researchers said on Tuesday. They found patients who stayed on...